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Bacitracin from B. licheniformis and B. subtilis
strains represents a mixture of nine cyclic polypep-
tides and the most important component is baci-
tracin A. It has bactericidal properties against Gram
(+) bacteria and is used in treatment of skin, eye, and
ear infections. Because bacitracin demonstrates
local action and is not absorbed through mucous
membrane, then it is possible to use it in treatment
of patients with pseudomembranous enterocolitis.
Bacitracin is mostly administered in the form of
drops and ointments, in complex preparations with
neomycin (1, 2). Structure of bacitracin A used in
therapy is presented in Figure 1.
Since 1975, dabsyl chloride (DBS) is used for
identification of N-terminal amino acid in polypep-
tide chain during analysis of compounds containing
amine group (3). The first step in the process is con-
densation of DBS with polypeptide through N-ter-
minal amino acid. The second step is hydrolysis in
acidic environment that results in a product ñ sulfon-
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Abstract: A fast spectrophotometric method has been developed for bacitracin identification and determination
after condensation reaction with dabsyl chloride. In addition, determination of dye stability of sulfonamide
derivative and identification of the molar ratio of reagents was done at various time-points. The developed
method has a good linearity with very broad spectrum, correlation coefficient of r = 0.9972, good precision
(RSD = 1.54 ± 0.11%), and recovery at three different levels of concentration was found between 98.33% and
103.47%. Usefulness of the method was demonstrated by positive results obtained during determination of bac-
itracin concentration in bulk drug.
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Name Molecular formula X Y R
Bacitracin A C66H103N17O16S L-Ile L-Ile CH3
Bacitracin B1 C65H101N17O16S L-Ile L-Ile H
Bacitracin B2 C65H101N17O16S L-Val L-Ile CH3
Bacitracin B3 C65H101N17O16S L-Ile L-Val CH3
Figure 1. Structure and different types of bacitracin according to FP VIII
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amide derivative. The final, third, step is chromato-
graphic identification of obtained product. This
reaction is highly sensitive (10-9 ñ 10-10 mol/dm3).
Published data demonstrate wide application of
chromatographic techniques with varied methods of
detection like HPLC-MS, HPLC-UV, MEKC
(4ñ10). TLC method with densitometric detection
with co-occurrence of neomycin in the study mate-
rial was also used in the quantitative determination
of bacitracin (11, 12). 
In this paper, the quantitative determination of
bacitracin after condensation reaction with dabsyl
chloride is presented. Modification in the method of
N-terminal amino acid determination with the use of
DBS was done by exclusion of hydrolysis and estab-
lishing reaction conditions to enable direct spec-
trophotometric estimation of the product of DBS
reaction with the antibiotic. 
ANALYSIS
Reagents
Bacitracin from B. licheniformis (Sigma, St.
Louis, USA), dabsyl chloride = 97.5% (AT) (Fluka
Figure 2. The UV spectrum of the product of bacitracin-DBS condensation.
Figure 3. Changes in the absorbance dependent on the molar ratio of DBS : bacitracin
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Chemie AG, Buchs, Switzerland), acetone p.a. sodi-
um carbonate p.a. and sodium bicarbonate p.a.
(POCh Gliwice, Poland).
Bacitracin used for the experiments met the
requirements described in a monograph in Polish
Pharmacopoeia (FP VIII) in the scope of identity,
purity and biological activity.
Instruments and software
UV/Vis spectrophotometer Cary 100 Conc.
Varian, 10 mm glass cells, STATISTICA 9 soft-
ware.
Formation of bacitracin derivative with dabsyl
chloride
A product of reaction was formed when 0.06
mL of bacitracin solution (1◊10-3 mol/dm3) in car-
bonate buffer (pH = 9.0) was mixed with 0.6 mL of
dabsyl chloride solution (1◊10-3 mol/dm3), heated up
at 70OC for 15 min, then cooled down to 25OC and
adjusted with acetone to the final volume of 5.0 cm3.
The product demonstrated characteristic absorption
spectrum in a range 400 nm to 800 nm with maxi-
mum at λ = 474 nm.
Absorption spectrum of the formed product,
recorded in the presence of reference material pre-
pared in the same way as a study sample, is present-
ed in Figure 2.
In the above-described conditions, no absorp-
tion of separate bacitracin and DBS solutions was
recorded in a studied range of measurement.
Therefore, it may be assumed that the absorbance
value at the maximum of absorption originates from
a product obtained in a reaction of the studied
reagents. 
Further studies estimated the product in the
context of its use to develop a new method.
Determination of the molar ratio of reagents
In flasks of 5 cm3 volume, a series of 9 solu-
tions with the same concentration of bacitracin
(2◊10-5 mol/dm3) and increasing concentration of
DBS (1◊10-5 ñ 2◊10-4 mol/dm3) was prepared. A ref-
erence material containing identical volume of car-
bonate buffer (pH = 9.00) and DBS concentration as
in the study sample was prepared for each individual
sample. The samples and their references were heat-
ed up in water bath at 70OC for 15 min, and then
cooled down and adjusted with acetone to the final
volume of 5 cm3. Absorbance was measured in rela-
tion to appropriate reference material. A graph pre-
senting dependence of absorbance at 474 nm
towards the molar ratio of DBS to bacitracin was
created. This graph indicates quantitative run of the
reaction with molar ratio 1:6, bacitracin : DBS (Fig.
3). 
Stability of color in solutions 
Stability of color in solutions was studied by
measurement of samples absorbance at λ = 474 nm
Figure 4. Changes in the solutions absorbance in time
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from 0 to 240 min after termination of incubation.
The recorded changes of absorbance value at a par-
ticular time are presented in Figure 4. Results of
these studies confirmed stability of color in solu-
tions after 30 min from termination of incubation
which was kept at a constant level for the next 2 h. 
Linearity
In order to determine a dependence of
absorbance of solutions on the content of antibiotics,
a series of solutions with increasing concentration of
bacitracin (2◊10-6 to 2◊10-5 mol/dm3) and constant
concentration of DBS (1.2◊10-4 mol/dm3) were pre-
pared based on the earlier determined molar ratio of
reagents. A series consisting of 6 samples contain-
ing bacitracin with reference material was incubated
in water bath at 70OC for 15 min. Then, the samples
were cooled down to 25OC and completed with ace-
tone to 5 cm3. The absorbance of samples was
recorded at λ = 474 nm. A graph representing the
dependence of absorbance on concentration of baci-
tracin in the sample had a good correlation coeffi-
cient, r = 0.9972 (Fig. 5).
Absorption coefficient
In the above-described conditions, values of
molar absorption coefficient (ε474nm = 2.4◊104) and
coefficient A1%1cm= 168 were obtained during studies
of linearity A = f(c).
Limit of Detection (LOD) and Limit of
Quantitation (LOQ)
Based on parameters of the curve, the LOD and
LOQ (mol/dm3) values were 1.08◊10-10 and 3.28◊10-10,
Figure 5. Dependence of the solutions absorbance on bacitracin concentration
Table 1. Precision of the method.
Concentration level of Measured absorbance RSD
bacitracin in sample values 
S
[%]
50% 0.1637; 0.1588; 0.1602; 0.1629; 0.1594; 0.1580 2.30◊10-3 1.43
100% 0.2875; 0.2849; 0.2861; 0.2795; 0.2921; 0.2906 4.48◊10-3 1.56
150% 0.3681; 0.3842; 0.3796; 0.3823; 0.3779; 0.3718 5.81◊10-3 1.65
S = standard deviation, RSD = relative standard deviation
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respectively. These values corresponded to low con-
centrations of bacitracin and at the same time indi-
cated satisfactory sensitivity of the method.
Precision
For precision determination, six samples with
three different concentrations of bacitracin (50%,
100% and 150%) were prepared. The samples with
reference material were heated up in water bath at
70OC for 15 min and then cooled down and adjusted
with acetone to the scale mark. The absorbance was
recorded at λ = 474 nm. The obtained values of
absorbance as well as calculated standard deviation
(S) and relative standard deviation (RDS) values are
presented in Table 1.
Recovery
Recovery was determined based on identified
concentration in relation to weighted amount under
conditions of developed method. For studies, 3
replicates at three different concentrations of the
antibiotic (80%, 100% and 120%) were prepared.
The obtained values of absorbance, which were used
for estimation of bacitracin recovery, are presented
in Table 2. 
Determination of bacitracin in bulk drug
A solution of bacitracin (1◊10-3 mol/dm3) in
carbonate buffer at pH = 9.00 as well as 6 identical
mixtures of DBS with bacitracin solutions (1.2◊10-5
mol/dm3) were prepared. The absorbance of solu-
tions was recorded at λmax = 474 nm. Concentration
of bacitracin in the samples was calculated based on
the slope obtained for calibration curve. The
obtained values of absorbance and corresponding
with them concentrations of bacitracin as well as the
percentage ratio to weighted amounts are presented
in Table 3. 
In bulk drug, concentration of bacitracin was in
a range 100 ± 1.67%.
Table 2. Bacitracin recovery values expressed as a percentage for three various levels of concentration.
Concentration level Weighted bacitracin Measured Average
of bacitracin A474 nm concentration bacitracin concentration
Recovery
recovery




80% 0.2279 9.60◊10-6 9.81◊10-6 102.17 100.86 
0.2215 9.46◊10-6 98.52
0.2677 1.20◊10-5 100.00
100% 0.2648 1.20◊10-5 1.18◊10-5 98.33 99.17
0.2653 1.19◊10-5 99.17
0.3215 1.49◊10-5 103.47
120% 0.3090 1.44◊10-5 1.42◊10-5 98.61 101.62
0.3198 1.48◊10-5 102.78 
A474 nm = absorbance at 474 nm
Table 3. The amount of bacitracin in bulk drug.
Average absorbance Bacitracin concentration Amounts






0.2653 1.18◊10-5 9 8.33
xúr= 1.20◊10-5 xúr= 100.00
S= 1.90◊10-7 S= 1.58
RSD = 1.58% RSD= 1.58%
µ0.05 = 1.20◊10-5 ± 1.18◊10-7 µ0.05 = 100.00 ± 0.99  
xúr = average [mol/dm3], S = standard deviation, RSD = relative standard deviation, µ = confidence interval
858 JAN KRZEK and JOANNA PIOTROWSKA
RESULTS AND DISCUSSION
Reaction of free amine groups with dabsyl
chloride was used for development of a new method
for determination of bacitracin in bulk drug. It was
observed that molar ratio of DBS to bacitracin in
reaction of condensation was 6:1. The product was
stable for 2 h.
The method demonstrated high sensitivity
(LOD = 1.08◊10-10 mol/dm3 and LOQ = 3.28◊10-10
mol/dm3), good precision for various levels of con-
centration (RSD = 1.43% to 1.65%) and high accu-
racy expressed as a percentage of recovery (98.33%
to 103.47%). The dependence of absorbance on con-
centration was straight in a range 2◊10-6 to 2◊10-5
mol/dm3. The results of determination of bacitracin
in bulk drug are characterized by narrow confidence
interval, which is a confirmation of practical usabil-
ity of the method developed for controlling raw
material during production. 
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